Sodium Channel Platform
Comprehensive Portfolio of Cell Lines and Assay for Nav1.1 - Nav1.9
Icagen scientists identified and developed the first selective small molecule inhibitors of Nav1.7 and Nav1.8 and more recently the capability to prosecute drug discovery against the historically challenging sodium channel pain target Nav1.9. Through these discovery efforts Icagen created a sophisticated portfolio of Nav reagents, assays, and technologies. Clients gain access to Icagen’s expertise and validated tools through our sodium channel portfolio. Icagen scientists are also available to create custom sodium channel cell lines and assays.
Icagen’s success in prosecuting drug candidate discovery programs for Nav channels is built upon an industry leading portfolio of cell lines expressing all Nav channel subtypes (human and many species orthlogs) complemented by a broad set of validated fluorescence, flux and electrophysiological assay platforms. This unmatched portfolio of tools enables our staff to conduct high throughput screening of >500K compound libraries, evaluate Nav channel potency and subtype selectivity, and determine species ortholog activity. In addition we can assess mechanism-of-action, site-of-action and offer detailed biophysical and pharmacological analysis.
Our comprehensive portfolio of sodium channels, including species orthologs, enables high throughput selectivity profilinging.
Icagen can provide customers detailed analysis of Nav channel biophysical properties as well as pharmacological evaluation of human Nav channels and species orthologs as well as Nav channels carrying disease causing mutations.
High throughput assay development, implementation and execution for even then most challenging of Nav channel targets.